The quaternary benzo[c]phenanthridine alkaloid chelerythrine is widely used as an inhibitor of protein kinase C (PKC). However, in biological systems chelerythrine interacts with an array of proteins. In this study, we examined the effects of chelerythrine and sanguinarine on conventional PKCs (cPKCs) and PKC upstream kinase, phosphoinositide-dependent protein kinase 1 (PDK1), under complete inhibition conditions of PKC-dependent oxidative burst. In neutrophil-like HL-60 cells, sanguinarine and chelerythrine inhibited N-formyl-Met-Leu-Phe, phorbol 12-myristate 13-acetate (PMA)-, and A23187-induced oxidative burst with IC(50) values not exceeding 4.6 micromol/L, but the inhibition of PMA-stimulated cPKC activity in intact cells required at least fivefold higher alkaloid concentrations. At concentrations below 10 micromol/L, sanguinarine and chelerythrine prevented phosphorylation of approximately 80 kDa protein and sequestered approximately 60 kDa phosphoprotein in cytosol. Moreover, neither sanguinarine nor chelerythrine impaired PMA-stimulated translocation of autophosphorylated PKCalpha/betaII isoenzymes, but both alkaloids induced dephosphorylation of the turn motif in PKCalpha/betaII. The dephosphorylation did not occur in unstimulated cells and it was not accompanied by PKC degradation. Furthermore, cell treatment with sanguinarine or chelerythrine resulted in phosphorylation of approximately 70 kDa protein by PDK1. We conclude that PKC-dependent cellular events are affected by chelerythrine primarily by multiple protein interactions rather than by inhibition of PKC activity.

Department of Medical Chemistry and Biochemistry Faculty of Medicine Palacky University Olomouc Czech Republic

000      

03665naa 2200505 a 4500

001      

bmc11006427

003      

CZ-PrNML

005      

20121127122105.0

008      

110401s2008 ne e eng||

009      

AR

040    __

$a ABA008 $b cze $c ABA008 $d ABA008 $e AACR2

041    0_

$a eng

044    __

$a ne

100    1_

$a Vrba, Jiří, $d 1971- $7 xx0042118

245    10

$a Conventional protein kinase C isoenzymes undergo dephosphorylation in neutrophil-like HL-60 cells treated by chelerythrine or sanguinarine / $c J. Vrba, Z. Dvořák, J. Ulrichová, M Modrianský

314    __

$a Department of Medical Chemistry and Biochemistry, Faculty of Medicine, Palacky University, Olomouc, Czech Republic. vrbambv@seznam.cz

520    9_

$a The quaternary benzo[c]phenanthridine alkaloid chelerythrine is widely used as an inhibitor of protein kinase C (PKC). However, in biological systems chelerythrine interacts with an array of proteins. In this study, we examined the effects of chelerythrine and sanguinarine on conventional PKCs (cPKCs) and PKC upstream kinase, phosphoinositide-dependent protein kinase 1 (PDK1), under complete inhibition conditions of PKC-dependent oxidative burst. In neutrophil-like HL-60 cells, sanguinarine and chelerythrine inhibited N-formyl-Met-Leu-Phe, phorbol 12-myristate 13-acetate (PMA)-, and A23187-induced oxidative burst with IC(50) values not exceeding 4.6 micromol/L, but the inhibition of PMA-stimulated cPKC activity in intact cells required at least fivefold higher alkaloid concentrations. At concentrations below 10 micromol/L, sanguinarine and chelerythrine prevented phosphorylation of approximately 80 kDa protein and sequestered approximately 60 kDa phosphoprotein in cytosol. Moreover, neither sanguinarine nor chelerythrine impaired PMA-stimulated translocation of autophosphorylated PKCalpha/betaII isoenzymes, but both alkaloids induced dephosphorylation of the turn motif in PKCalpha/betaII. The dephosphorylation did not occur in unstimulated cells and it was not accompanied by PKC degradation. Furthermore, cell treatment with sanguinarine or chelerythrine resulted in phosphorylation of approximately 70 kDa protein by PDK1. We conclude that PKC-dependent cellular events are affected by chelerythrine primarily by multiple protein interactions rather than by inhibition of PKC activity.

590    __

$a bohemika - dle Pubmed

650    _2

$a alkaloidy $x farmakologie $x chemie $7 D000470

650    _2

$a benzofenantridiny $x farmakologie $x chemie $7 D053119

650    _2

$a buněčná smrt $x účinky léků $7 D016923

650    _2

$a bezbuněčný systém $7 D002474

650    _2

$a vztah mezi dávkou a účinkem léčiva $7 D004305

650    _2

$a HL-60 buňky $7 D018922

650    _2

$a lidé $7 D006801

650    _2

$a izoenzymy $x metabolismus $7 D007527

650    _2

$a isochinoliny $x farmakologie $x chemie $7 D007546

650    _2

$a NADPH-oxidasy $x metabolismus $7 D019255

650    _2

$a neutrofily $x cytologie $x enzymologie $x účinky léků $7 D009504

650    _2

$a fosforylace $x účinky léků $7 D010766

650    _2

$a proteinkinasa C $x metabolismus $7 D011493

650    _2

$a transport proteinů $x účinky léků $7 D021381

650    _2

$a protein-serin-threoninkinasy $x metabolismus $7 D017346

650    _2

$a respirační vzplanutí $x účinky léků $7 D016897

650    _2

$a substrátová specifita $x účinky léků $7 D013379

655    _2

$a práce podpořená grantem $7 D013485

700    1_

$a Dvořák, Zdeněk, $d 1974- $7 xx0118950

700    1_

$a Ulrichová, Jitka, $d 1956- $7 ola2002158251

700    1_

$a Modrianský, Martin, $d 1966- $7 xx0042117

773    0_

$t Cell Biology & Toxicology $w MED00005739 $g Roč. 24, č. 1 (2008), s. 39-53

910    __

$a ABA008 $b x $y 2

990    __

$a 20110414104154 $b ABA008

991    __

$a 20121127122131 $b ABA008

999    __

$a ok $b bmc $g 834019 $s 698528

BAS    __

$a 3

BMC    __

$a 2008 $x MED00005739 $b 24 $c 1 $d 39-53 $m Cell biology and toxicology $n Cell Biol Toxicol

LZP    __

$a 2011-1B09/jjme